PMID- 30924705
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20200720
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 30
IP  - 2
DP  - 2020 Mar
TI  - Danaparoid is effective and safe for patients with obstetric antiphospholipid 
      syndrome.
PG  - 332-337
LID - 10.1080/14397595.2019.1602241 [doi]
AB  - Objectives: The objective is to evaluate whether danaparoid is effective in 
      improving the live birth rate in patients with obstetric antiphospholipid 
      syndrome (oAPS).Methods: This prospective study included 91 pregnancies of 60 
      patients with oAPS diagnosed according to criteria of the International Congress 
      on APS. Live birth rates, adverse pregnancies and perinatal outcomes were 
      compared among patients treated with danaparoid and low dose aspirin (danaparoid 
      group, LDA), unfractionated heparin (UFH) and LDA (UFH group) and LDA and/or 
      prednisolone (LDA group).Results: After excluding 11 miscarriages with abnormal 
      embryonic chromosomes, one chemical pregnancy and one ectopic pregnancy, live 
      birth rates were 87.5% (14/16) for the danaparoid group, 90.0% (36/40) for the 
      UFH group and 63.6% (14/22) for the LDA group, respectively. The live birth rates 
      of patients treated with danaparoid and UFH were similar and tended to be higher 
      than that of patients treated with LDA, respectively (OR 4.0, 95% confidence 
      interval 0.72-22.22 and 5.15, 1.33-20.00). No patient given danaparoid and one 
      patient with UFH developed heparin-induced thrombocytopenia which resulted in a 
      stillbirth. Another patient with UFH suffered a lumbar compression 
      fracture.Conclusion: Danaparoid is effective for improving the live birth rate 
      and is safe for patients with oAPS.
FAU - Yoshihara, Hiroyuki
AU  - Yoshihara H
AD  - Department of Obstetrics and Gynecology, Nagoya City University, Graduate School 
      of Medical Sciences, Nagoya, Japan.
FAU - Sugiura-Ogasawara, Mayumi
AU  - Sugiura-Ogasawara M
AD  - Department of Obstetrics and Gynecology, Nagoya City University, Graduate School 
      of Medical Sciences, Nagoya, Japan.
FAU - Kitaori, Tamao
AU  - Kitaori T
AD  - Department of Obstetrics and Gynecology, Nagoya City University, Graduate School 
      of Medical Sciences, Nagoya, Japan.
FAU - Katano, Kinue
AU  - Katano K
AD  - Obstetrics & Gynecology Katano Clinic, Kasugai, Japan.
FAU - Ozaki, Yasuhiko
AU  - Ozaki Y
AD  - Department of Obstetrics and Gynecology, Nagoya City University, Graduate School 
      of Medical Sciences, Nagoya, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190424
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Fibrinolytic Agents)
RN  - 24967-94-0 (Dermatan Sulfate)
RN  - 9007-28-7 (Chondroitin Sulfates)
RN  - 9050-30-0 (Heparitin Sulfate)
RN  - BI6GY4U9CW (danaparoid)
SB  - IM
MH  - Adult
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Chondroitin Sulfates/administration & dosage/adverse effects/*therapeutic use
MH  - Dermatan Sulfate/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Heparitin Sulfate/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pregnancy Outcome
OTO - NOTNLM
OT  - Antiphospholipid syndrome
OT  - danaparoid
OT  - lupus anticoagulant
OT  - recurrent miscarriage
OT  - recurrent pregnancy loss
EDAT- 2019/03/30 06:00
MHDA- 2020/07/21 06:00
CRDT- 2019/03/30 06:00
PHST- 2019/03/30 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2019/03/30 06:00 [entrez]
AID - 10.1080/14397595.2019.1602241 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2020 Mar;30(2):332-337. doi: 10.1080/14397595.2019.1602241. Epub 
      2019 Apr 24.